Catalyst Pharmaceuticals Inc (CPRX) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds trimming or exiting versus the previous quarter.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, that develops and sells medicines for rare diseases. Its lead product is Firdapse (amifampridine), a potassium channel blocker approved by the U.S. Food and Drug Administration in November 2018 for Lambert-Eaton myasthenic syndrome (LEMS), a rare neuromuscular disorder in which faulty signalling between nerves and muscles causes weakness, mostly in the limbs. Firdapse was launched commercially in January 2019, and the approval was later extended to children aged six and older. The company's portfolio also includes Agamree (vamorolone), a treatment for Duchenne muscular dystrophy, and Fycompa (perampanel), an anti-seizure medicine. Because LEMS affects only a small number of people, roughly 3.4 per million, Catalyst's business is built around a small patient population, specialist prescribers and a patient support programme, rather than mass-market prescribing.
This page's picture is thin. In the 2026 second-quarter 13F filings, only one of the 149 tracked super-investor funds still held Catalyst, and two more had left: Third Avenue Management held 210,161 shares, a 1.06% weight in its portfolio, unchanged from the previous quarter, while Fundsmith and Deerfield Management both exited. No tracked fund opened a new position or added to one, and two funds trimmed or exited versus the previous quarter. The page shows no recent closing price in its range, so there is no price move to report since the quarter ended on June 30, 2026.
The other lenses on the page are also blank. No Form 4 insider transactions were parsed in the 90 days to November 13, 2026, and no congressional STOCK Act transactions were parsed in the window to November 11, 2026. The stock passes none of the tracked screens, no red flags are listed, and the index holds no Form 8-K filings for the ticker from January 2023 to the present. In short, the page records a single remaining super-investor holder and two exits, with no insider, congressional or corporate-filing activity to set against it.
Third Avenue Management — 1 tracked fund hold CPRX. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
No closely related stocks by co-holding for this stock. Browse all stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Third Avenue Management | 1.06% | 210,161 | HELD Q3 filed Nov 13 |
| Fundsmith | — | — | EXITED |
| Deerfield Management | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
This stock does not currently pass any tracked screen.
No Form 8-K filings for this ticker in the index (Jan 2023 – present).
Stocks A–Z · Track Record: how the signals scored · Practice timing on CPRX
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.